PMC:7195088 / 29431-29724 JSONTXT

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T22","span":{"begin":277,"end":282},"obj":"Body_part"}],"attributes":[{"id":"A22","pred":"uberon_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/UBERON_0002542"}],"text":"Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs. lopinavir/ritonavir plus interferon beta-1a vs. remdesivir vs. standard of care in patients with COVID-19. Double-blind, adaptive RCT (NCT04315948, recruiting). Primary endpoint: severity rating on a 7-point ordinal scale at day 15."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T150","span":{"begin":158,"end":166},"obj":"Disease"}],"attributes":[{"id":"A150","pred":"mondo_id","subj":"T150","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs. lopinavir/ritonavir plus interferon beta-1a vs. remdesivir vs. standard of care in patients with COVID-19. Double-blind, adaptive RCT (NCT04315948, recruiting). Primary endpoint: severity rating on a 7-point ordinal scale at day 15."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T161","span":{"begin":259,"end":262},"obj":"http://purl.obolibrary.org/obo/CLO_0001608"}],"text":"Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs. lopinavir/ritonavir plus interferon beta-1a vs. remdesivir vs. standard of care in patients with COVID-19. Double-blind, adaptive RCT (NCT04315948, recruiting). Primary endpoint: severity rating on a 7-point ordinal scale at day 15."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T388","span":{"begin":14,"end":33},"obj":"Chemical"},{"id":"T389","span":{"begin":14,"end":23},"obj":"Chemical"},{"id":"T390","span":{"begin":24,"end":33},"obj":"Chemical"},{"id":"T391","span":{"begin":38,"end":56},"obj":"Chemical"},{"id":"T392","span":{"begin":61,"end":80},"obj":"Chemical"},{"id":"T393","span":{"begin":61,"end":70},"obj":"Chemical"},{"id":"T394","span":{"begin":71,"end":80},"obj":"Chemical"},{"id":"T395","span":{"begin":86,"end":96},"obj":"Chemical"},{"id":"T396","span":{"begin":97,"end":101},"obj":"Chemical"},{"id":"T397","span":{"begin":109,"end":119},"obj":"Chemical"}],"attributes":[{"id":"A388","pred":"chebi_id","subj":"T388","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A389","pred":"chebi_id","subj":"T389","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A390","pred":"chebi_id","subj":"T390","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A391","pred":"chebi_id","subj":"T391","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A392","pred":"chebi_id","subj":"T392","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A393","pred":"chebi_id","subj":"T393","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A394","pred":"chebi_id","subj":"T394","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A395","pred":"chebi_id","subj":"T395","obj":"http://purl.obolibrary.org/obo/CHEBI_52999"},{"id":"A396","pred":"chebi_id","subj":"T396","obj":"http://purl.obolibrary.org/obo/CHEBI_10545"},{"id":"A397","pred":"chebi_id","subj":"T397","obj":"http://purl.obolibrary.org/obo/CHEBI_145994"}],"text":"Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs. lopinavir/ritonavir plus interferon beta-1a vs. remdesivir vs. standard of care in patients with COVID-19. Double-blind, adaptive RCT (NCT04315948, recruiting). Primary endpoint: severity rating on a 7-point ordinal scale at day 15."}

{"project":"LitCovid-sentences","denotations":[{"id":"T227","span":{"begin":168,"end":221},"obj":"Sentence"},{"id":"T228","span":{"begin":222,"end":293},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs. lopinavir/ritonavir plus interferon beta-1a vs. remdesivir vs. standard of care in patients with COVID-19. Double-blind, adaptive RCT (NCT04315948, recruiting). Primary endpoint: severity rating on a 7-point ordinal scale at day 15."}